Modalis Therapeutics (TSE:4883) Total Assets : 円1,559.12 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics Total Assets?

Modalis Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was 円1,559.12 Mil.

During the past 12 months, Modalis Therapeutics's average Total Assets Growth Rate was -23.90% per year. During the past 3 years, the average Total Assets Growth Rate was -45.00% per year. During the past 5 years, the average Total Assets Growth Rate was 44.60% per year.

During the past 6 years, Modalis Therapeutics's highest 3-Year average Total Assets Growth Rate was 288.20%. The lowest was -45.00%. And the median was 34.30%.

Total Assets is connected with ROA %. Modalis Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -102.19%. Total Assets is also linked to Revenue through Asset Turnover. Modalis Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Modalis Therapeutics Total Assets Historical Data

The historical data trend for Modalis Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics Total Assets Chart

Modalis Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

3,938.43

6,277.02

6,069.14

3,129.83

2,025.93

Modalis Therapeutics Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial														2,899.42	2,855.66	2,179.18	2,025.93	1,559.12

Modalis Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Modalis Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	1380.422	+	645.503
	=	2,025.93

Modalis Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	1011.664	+	547.46
	=	1,559.12

Modalis Therapeutics (TSE:4883) Total Assets Explanation

Total Assets is connected with ROA %.

Modalis Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-1831.744	/	( (2025.925	+	1559.124)	/ 2 )
	=	-1831.744	/	1792.5245
	=	-102.19 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Modalis Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (2025.925	+	1559.124)	/ 2 )
=	0	/	1792.5245
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Modalis Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Modalis Therapeutics (TSE:4883) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026

Website

https://www.modalistx.com

Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics (TSE:4883) Headlines

No Headlines